You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Peptide Based Therapy for Lung Fibrosis
SBC: Novici Biotech LLC Topic: NHLBIDESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Real Time Oxygen Monitoring for Tissue Health Peripheral Artery Disease Application
SBC: PROFUSA, INC. Topic: NHLBIDESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Skin Sympathetic Nerve Activity and Cardiac Arrhythmias
SBC: ARRHYTHMOTECH Topic: NIDADESCRIPTION provided by applicant The objective of this Phase II STTR grant application is to continue the R Randamp D efforts initiated in Phase I The long term objective for Arrhythmotech is to develop and market an instrument for the simultaneous recording of sympathetic nerve activity SNA and electrocardiogram ECG using electrodes on the skin This method neuECG was discovered in Dr ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Macromolecule Crystallization Screening Results Analysis
SBC: iXpressGenes, Inc. Topic: 100Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Retrofittable and Transparent Super-Insulator for Single-Pane Windows
SBC: NANOSD, INC. Topic: DEFOA0001429NanoSD, Inc. with its partners will develop a transparent, nanostructured thermally insulating film that can be applied to existing single-pane windows to reduce heat loss. To produce the nanostructured film, the team will create hollow ceramic or polymer nanobubbles and consolidate them into a dense lattice structure using heat and compression. Because it is mostly air, the resulting nanobubble s ...
STTR Phase II 2016 Department of EnergyARPA-E -
Pharmacological chaperones for the treatment of Open-Angle Glaucoma
SBC: Viewpoint Therapeutics, Inc. Topic: NEIOpen-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Genes-to-Molecules Platform for Expanding Natural Product Diversity
SBC: Lassogen, Inc. Topic: NCCIHProject Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community
SBC: EPERTURE LLC Topic: NIAProject Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension
SBC: Technology Commercialization Partners LLC Topic: NHLBIABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Detection of perfuorooctanoic acid (PFOA) and perfluorooctane sulfonate(PFOS) in liquid samples.
SBC: SEACOAST SCIENCE, INC. Topic: NIEHSPerfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate) are toxic and persistent compounds resulting from the production and use of fluoropolymers such as Gortex® and Teflon ®. The structure of PFAS preclude environmental degradation and can lead to bioaccumulation in animals and humans. Reported adverse effects of these compounds in humans include: ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health